Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329809 | 1.00 | GPR4 (0.52) | GPR4KCNH2HRH3AGTR1AGTR2 | |
| SCHEMBL4336830 | 0.85 | GPR4 (0.65) | GPR4KCNH2HRH3 | |
| SCHEMBL4336824 | 0.85 | GPR4 (0.65) | GPR4KCNH2HRH3 | |
| SCHEMBL4456264 | 0.83 | AGTR1 (0.44) | GPR4KCNH2HRH3AGTR1AGTR2 | |
| SCHEMBL4456259 | 0.83 | AGTR1 (0.44) | GPR4KCNH2HRH3AGTR1AGTR2 | |
| SCHEMBL4366680 | 0.82 | GPR4 (0.79) | GPR4KCNH2HRH3AGTR1 | |
| SCHEMBL4366676 | 0.82 | GPR4 (0.79) | GPR4KCNH2HRH3AGTR1 | |
| SCHEMBL4322086 | 0.82 | GPR4 (0.67) | GPR4KCNH2HRH3 | |
| SCHEMBL4322079 | 0.82 | GPR4 (0.67) | GPR4KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL4320357 | 0.81 | GPR4 (0.77) | GPR4KCNH2HRH3AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009144201-A1 | IMIDAZOPYRIDINE DERIVATIVES AS GPR4 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009144201-A1 | IMIDAZOPYRIDINE DERIVATIVES AS GPR4 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-12-03 | — | — | WO | disclosed |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | TARACIDO IVAN CORNELLA | 2009-11-26 | — | — | US | disclosed |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | TARACIDO IVAN CORNELLA | 2009-11-26 | — | — | US | disclosed |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | TARACIDO IVAN CORNELLA | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | FLT4, UACA, FLT1 | GPR4 119/4885KCNH2 1427/4885HRH3 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.